Immune Pharmaceuticals (IMNP) Stock Price, News & Analysis

Company Overview

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 12.29 million shs
• Market Capitalization: $8.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IMNP Stock Analysis - Frequently Asked Questions

How were Immune Pharmaceuticals' earnings last quarter?

Immune Pharmaceuticals Inc (NASDAQ:IMNP) released its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.05.

What other stocks do shareholders of Immune Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immune Pharmaceuticals investors own include Neovasc (NVCN), LadRx (CYTR), Biopharmx (BPMX), Synergy Pharmaceuticals (SGYP), Gevo (GEVO), Sorrento Therapeutics (SRNE) and Novavax (NVAX).

Company Calendar

• Last Earnings: 5/15/2018
• Today: 6/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:IMNP
• Previous Symbol: OTCMKTS:EPCT
• CIK: 1208261
• Web: www.immunepharmaceuticals.com
• Phone: 201-464-2677
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 49,313,000
• Free Float: N/A
• Market Cap: $8.14 million
• Optionable: Not Optionable
• Beta: N/A